Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Allen

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Neuropharmacology|November 7, 2025
LSD microdosing in major depressive disorder: results from an open-label trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|February 19, 2026
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a phase 2a trialDimitri Daldegan-Bueno, Carina Joy Donegan, Rachael Sumner, et al.
Pilot and Feasibility Studies|October 5, 2023
An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)Carina Joy Donegan, Dimitri Daldegan-Bueno, Rachael Sumner, et al.
Trials|August 24, 2024
LSDDEP2: study protocol for a randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorderDimitri Daldegan-Bueno, Carina Joy Donegan, Anna Forsyth, et al.
Pageof 4